Background:
Inhibition of autophagy is reported to be a therapeutically effective strategy in overcoming the resistance that is
a deadly outcome in cancer. One of the most common reasons for chemo-resistance to treatment is the patients with tumors exhibiting a
KRAS mutation which occurs in approximately 40% of colorectal cancer patients.
Objective:
Hence, we assessed whether a palladium (Pd)(II) complex is a promising anticancer complex, compared to 5-fluorouracil in
KRAS wt HT-29 and KRAS mutant HCT-15 cells.
Methods:
HCT-15 and HT-29 cells were used for colorectal cancer and chloroquine (CQ) was used as an inhibitor of autophagy. In this
context, cells were treated with Pd(II) complex and 5-FU in combination with CQ for 48 h and cell viability was measured by SRB assay.
Cell death mode was examined with M30 and M65 ELISA assays, annexin V/propidium iodide. Autophagy was determined by acridine
orange (AO) staining. Furthermore, the
expression of various autophagy and apoptosis related proteins were evaluated with Western blotting.Luminex assay and reactive oxygen
species (ROS) level were examined.
Results:
Cell viability was decreased in a dose dependent matter and CQ enhances cytotoxic effect in Pd(II) and 5-FU treated cells in
colorectal cancer cells. Our data showed that inhibition of autophagic flux significantly increase intrinsic apoptosis through the activation
of ROS. We showed that combinatorial treatment with CQ induces apoptosis via the caspase-dependent mitochondrial pathway. Luminex
analysis revealed that the combination resulted in a down-regulation of a NF-κB/AKT/CREB signaling pathways in both cell line,
however, decreased Erk1/2 protein expression was only observed after treated with CQ combination in HCT-15 cells.
Conclusion:
We suggest that inhibition of autophagy along with Pd(II) and 5-FU treatment has a synergistic effect in KRAS-mutant
colorectal cancer cells. Autophagy inhibition by CQ promotes apoptosis via blockade of the NF-κB/AKT/CREB and activation of ROS.
Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation
